TG Therapeutics, Inc. (NASDAQ:TGTX) saw its shares appreciate significantly in after-hours trading following the announcement of preliminary revenue estimates for the fourth quarter of 2025 and a positive financial outlook for the coming year. Investors responded favorably to the company's performance indicators, reflective of growing market confidence in TG Therapeutics' commercial execution and growth trajectory.
According to the early figures released by the firm, Briumvi, the company's primary product, is projected to generate approximately $182 million in net product revenue from U.S. sales during the final quarter of 2025. For the entirety of 2025, TG Therapeutics anticipates Briumvi's net revenue in the U.S. to reach roughly $594 million. When considering the global market, the company expects total revenue in 2025 to be close to $616 million, highlighting the significance of international sales in its overall revenue composition.
Looking ahead, the company has set an ambitious target for 2026, aiming for global total revenue in the range of $875 million to $900 million. Of this forecast, Briumvi's net product revenue in the U.S. is expected to contribute between $825 million and $850 million. This projection points to confidence in sustained growth and market expansion for Briumvi, a product that has evidently captured a meaningful share of its addressable market since its launch.
Michael Weiss, CEO of TG Therapeutics, emphasized the robust commercial performance of Briumvi through 2025, stating, "Briumvi continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi-billion dollar opportunity for Briumvi. With significant market share capture since launch, we believe TG Therapeutics is well positioned to drive long-term revenue growth and cash flow." This commentary underscores the strategic focus on capitalizing on Briumvi's market momentum and profitability potential.
In response to the disclosed financial outlook, TG Therapeutics' stock demonstrated notable positive price action. During Tuesday's extended trading session, shares increased by 6.60%, closing at $29.71, indicative of investor enthusiasm and optimism regarding the company's prospects.
Market analytics, such as those provided by Benzinga Pro, showed that TG Therapeutics has achieved substantial momentum, aligning with positive indicators in the growth and value metrics. Tools like Benzinga Edge further facilitate investor awareness by ranking top-performing stocks daily based on momentum, growth, value, and quality, helping stakeholders to identify key market leaders.
Overall, TG Therapeutics' preliminary revenues and forward-looking estimates suggest a promising trajectory for the company as it continues to deepen its market penetration and expand its revenue base globally. Monitoring the conversion of these revenue expectations into realized cash flows will remain critical in assessing the company's operational and financial health over the coming periods.